Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The industry rank for Carasent AB (publ)'s 9-Day RSI or its related term are showing as below:
OSTO:CARA's 9-Day RSI is ranked better than 51.08% of 695
companies
in the Healthcare Providers & Services industry
Industry Median: 50.59
vs OSTO:CARA: 50.31
Carasent AB (publ) (OSTO:CARA) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Carasent AB (publ) 9-Day RSI Related Terms
OSTO:CARA vs VEEV, BTSG, HQY: 9-Day RSI Comparison
For the Health Information Services subindustry, Carasent AB (publ)'s 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carasent AB (publ) 9-Day RSI vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Carasent AB (publ)'s 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Carasent AB (publ)'s 9-Day RSI falls into.
Carasent AB (publ) (OSTO:CARA) 9-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Carasent AB (publ) (OSTO:CARA) has a 9-Day RSI of 50.31 as of Aug. 21, 2026. According to the industry distribution chart, Carasent AB (publ) ranks #340 out of 695 companies in the Healthcare Providers & Services industry, placing it in the top 48.9%.
Is Carasent AB (publ)'s 9-Day RSI too high?
Carasent AB (publ)'s current 9-Day RSI is 50.31. The Healthcare Providers & Services industry median 9-Day RSI is 50.59. Carasent AB (publ)'s value of 50.31 is 0.6% below this industry median. Based on the distribution chart, Carasent AB (publ) ranks #340 out of 695 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Carasent AB (publ) has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Carasent AB (publ)'s 9-Day RSI compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Carasent AB (publ) ranks #340 out of 695 companies for 9-Day RSI. This puts Carasent AB (publ) in the upper half of its industry. The industry median 9-Day RSI is 50.59. Carasent AB (publ)'s value of 50.31 is 0.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Healthcare Providers & Services company?
The median 9-Day RSI among Healthcare Providers & Services companies is 50.59, based on 695 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Carasent AB (publ)'s current 9-Day RSI of 50.31 is 0.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median 9-Day RSI is 50.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carasent AB (publ)'s current 9-Day RSI is 50.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carasent AB (publ) stock overvalued right now?
Based on GuruFocus' analysis, Carasent AB (publ) (OSTO:CARA) is currently considered Modestly Undervalued. The stock's GF Value™ is kr28.64, compared to a current price of kr25.65 — trading 10.4% below its estimated fair value. The current 9-Day RSI is 50.31 and 0.6% below the Healthcare Providers & Services industry median of 50.59. Carasent AB (publ)'s overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Carasent AB (publ) (OSTO:CARA), the current 9-Day RSI is 50.31 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Carasent AB (publ) (OSTO:CARA) Overvalued in 2026?
Based on GuruFocus' analysis, Carasent AB (publ) stock appears to be undervalued.
The current stock price of kr25.65 is trading 10.4% below its estimated GF Value™ of kr28.64.
GuruFocus considers Carasent AB (publ) to be Modestly Undervalued.
Key valuation signals for OSTO:CARA:
9-Day RSI: 50.31
GF Value™: kr28.64 vs. price of kr25.65 (10.4% below fair value)
Industry Position: 0.6% below the Healthcare Providers & Services median (#340 of 695)
No single metric tells the full story. See the OSTO:CARA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Carasent AB (publ) Formerly Carasent AB is a comprehensive provider of cloudbased EHR solutions and platform services for various organizations within the healthcare sector. With Webdoc as the main product, the group offers a broad ecosystem of services, including solutions for patient communication and business intelligence. Geographically, the company operates in the Nordic region and Germany. It derives maximum revenue from Nordic Region. The solutions provides by the group are: Webdoc; Metodika; Medrave; HPI plustoo; Ad Curis; Ad Opus; Webcur; Data-AL; and Data-Cur.
73GF Score
Get the complete analysis for OSTO:CARA
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:CARA has been successfully added to your 
